Glecaprevir / Pibrentasvir

Rifabutin

Contraindicated.

Available pharmaceutical opinion

Document made available to the pharmacist to communicate a drug interaction to the doctor.

DOWNLOAD
Mechanism

Rifabutin at steady state may induce CYP 3A4 and P-gp and decrease the plasma concentration of Glecaprevir / Pibrentasvir.

Glecaprevir / Pibrentasvir

Pharmacodynamic effects

Possible decrease of clinical efficacy.

Recommendations

Avoid association.

Alternative solution(s)

Rifabutin

Pharmacodynamic effects

Recommendations

Alternative solution(s)

Monitor

Tests

Pharmacokinetic parameters

Comment

See glecaprevir/pibrentasvir + rifampin.

Comment
Reference